TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03076489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First Visit
Description: blood sample , morpho-anatomic measures (height, weight, hip and size), impedancemetry and resting energy expenditure by indirect calorimetry, sample of urine and faeces previously collected at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First Visit
Description: blood sample , morpho-anatomic measures (height, weight, hip and size), impedancemetry and resting energy expenditure by indirect calorimetry, sample of urine and faeces previously collected at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: on-line questionnaires
Description: The two on-line questionnaires (hedonic and caloric evaluation of foods and beverages on photos) will have to be completed by the volunteers between the first and the second visit to the University-Hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: on-line questionnaires
Description: The two on-line questionnaires (hedonic and caloric evaluation of foods and beverages on photos) will have to be completed by the volunteers between the first and the second visit to the University-Hospital.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: a cognitive two-choice test based on food and drink pictures, during fMRI. Before and after the fMRI session, an assessment of the state of hunger, thirst, and general status of the volunteer will be carried out using a numerical scale ranging from 1 to 10.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: a cognitive two-choice test based on food and drink pictures, during fMRI. Before and after the fMRI session, an assessment of the state of hunger, thirst, and general status of the volunteer will be carried out using a numerical scale ranging from 1 to 10.
Study: NCT01904396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carnitine
Description: Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
Study: NCT03604172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: The cognitive behavioral therapy intervention will consist of weekly, 50-minute individual meetings for 16 weeks with a clinician trained in cognitive behavioral therapy for binge eating disorder.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist
Description: The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered cognitive behavioral therapy.
Study: NCT03993886

Intervention type: DEVICE
Group type: OTHER
Intervention: CorBand
Description: The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.

Intervention type: DEVICE
Group type: OTHER
Intervention: CorBand
Description: The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.

Intervention type: DEVICE
Group type: OTHER
Intervention: CorBand
Description: The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.

Intervention type: DEVICE
Group type: OTHER
Intervention: CorBand
Description: The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.

Intervention type: OTHER
Group type: OTHER
Intervention: Activity Monitor
Description: commercially available accelerometer to be worn on wrist

Intervention type: OTHER
Group type: OTHER
Intervention: Bioimpedance spectrometer
Description: Commercially available bioimpedance monitor.

Intervention type: OTHER
Group type: OTHER
Intervention: ECG
Description: Commercially available electrocardiogram machine

Intervention type: OTHER
Group type: OTHER
Intervention: respiratory rate sensor
Description: Commercially available respiratory rate sensor.
Study: NCT04166370

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthened (Services and SBCC)
Description: Strengthening referrals to health services- Needed improvements to existing health referral networks will be assessed, identified and implemented. Peer leaders will refer PLW to nearby service delivery points.~Improving quality of health/nutrition services- Health-related service providers will be trained and supervised on nutrition best practices.~SBCC- Primarily target PLW. Delivered using traditional and digital channels. Text/voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for these messages. Female community nutrition promoters will also be deployed; delivering SBCC during group meetings and in health facilities. Mothers' groups will be established, and will be led by peer leaders, mentored in the delivery of messages on nutrition behavior.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthened (Services and SBCC) + CCT
Description: Will include all components of the strengthened intervention and participants will receive monthly cash transfers, which is about 25% of monthly consumption expenditure among poor rural households in Bangladesh. Cash transfers will begin when a woman enrolls (at any time during her pregnancy or until 2 months after giving birth). The monthly transfer will continue until a child is 12 months of age, thereby supporting mothers during the critical period of complementary food introduction. The transfer is contingent on having had a minimum of 4 ANC visits and monthly participation in mother's group SBCC sessions.
Study: NCT05131334

Intervention type: DEVICE
Group type: OTHER
Intervention: auriStim, for auricular vagal stimulation
Description: For auricular vagal stimulation we used auriStim (AU0115, Multisana GmbH, Vienna, Austria). Using a green light-emitting diode (LEDs) flashlight, blood vessels in the cymba conchae of the left ear side were detected. Minimal invasive needles (penetrating 1-2mm) were placed close to the vessel-bifurcation to provide efficient stimulation of the auricular branch of the vagus nerve. The built-in microchip controls monophasic volt pulses of 1 ms, with alternating polarity, a frequency of 1 Hz and an amplitude of 4V. Stimulation lasted for 72h in total with alternating on/off periods of three hours. Thereafter, the device was removed, and patients continued their therapy consisting of anti-withdrawal medication.
Study: NCT03073811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein enhanced nutrition intervention
Description: Participants will be provided 30 grams of high quality protein (Ensure Max) three times a day for two weeks before surgery and four weeks after surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Control
Description: provided educational on the role of nutrition to prepare for and heal from surgery, and Registered Dietitian will instruct participant to follow instruction on handout and one oral nutrition supplement per day for two week before surgery.
Study: NCT03931850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block
Description: Pudendal nerve block is the one of peripheral nerve block. Injection local anesthetic medication around this nerve can provide analgesia around perineal area.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal nerve block
Description: Pudendal nerve block is the one of peripheral nerve block. Injection local anesthetic medication around this nerve can provide analgesia around perineal area.
Study: NCT03192293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin/Simvastatin/Fulvestrant
Description: 7 days Lead-in period: Metformin: 850mg (one tablet) twice a day Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle.~Tumour biopsy at 8 weeks. Every 8 weeks for the first 6 months, every 12 weeks thereafter:~Performance status evaluation Medical history and physical examination Clinical tumor measurement Review of treatment-related side-effects Blood taking for research purpose and routine blood tests Routine scans
Study: NCT00118248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study: NCT03459469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegavivint
Description: This is an Investigational drug
Study: NCT04222699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin calcium ointment, 2%
Description: Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Chlorhexidine, 4%
Description: Chlorhexidine is an antiseptic that fights bacteria.~Topical chlorhexidine is used to clean the skin to prevent infection that may be caused by surgery, injection, or skin injury.
Study: NCT00700882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Study: NCT02901249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Study: NCT01263470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voglibose
Description: Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
Study: NCT04683952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise training with Humified High Flow Nasal Cannula
Description: The experimental group will be trained using HHFNC with the most adequate continuous flow, in a range between 25 and 30 L / min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training - Control Group
Description: The control group will perform exercise training in spontaneous breathing.
Study: NCT02913092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic sensor and OW education
Description: MDI sensor-generated alerts will be relayed via app platform on participant's phone and responded to (e.g. outreach worker contacts the patient for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide education over the phone
Study: NCT00056316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Skills Training: Experimental
Description: Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
Study: NCT03504475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine Hydrochloride Tablet 20 mg
Description: A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil® 20 mg
Description: Paxil® Tablet 20 mg will be used as a comparator drug for the bioequivalence study, manufactured by GlaxoSmithKline（Distributed by: Apotex Corp.）.
Study: NCT02820753

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR + (Text or Portal)
Description: Per protocol analysis:~Patients who received the initial 6 weeks of SMS messaging continuously, or logged on to the patient portal and completed at least one survey.
Study: NCT02290301

Intervention type: DRUG
Intervention: gemigliptin
Study: NCT03168581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN-105
Description: Patients with supratentorial intracerebral hemorrhage (ICH) will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants will receive CN-105 administered intravenously (IV) for a 30 -minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days)
Study: NCT02345629

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cordotomy
Description: Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cordotomy
Description: Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.
Study: NCT01288066

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hemiarthroplasty
Description: Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total arthroplasty
Description: Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
Study: NCT04413396

Intervention type: PROCEDURE
Intervention: Outpatient Parenteral Antibiotic Therapy
Description: Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
Study: NCT03935100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic clipping
Description: Endoscopic clips fired to close mucosa over diverticular defects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - colonoscopy without clipping
Description: Colonoscopy performed, no clipping of diverticula
Study: NCT01087190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid treatment
Description: isoniazid 300 mg po qd for 9 months
Study: NCT02893514

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Screening Only (SO) condition
Description: Patient and PCP are not presented with screening results. The PCP does not receive clinical decision support, or clinical reminders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUSIT Condition
Description: Following completion of substance use screening, the tablet computer presents screening results (including level of risk) to the patient for each substance used, asks them to identify their drug of most concern (DOMC), and assesses readiness and confidence to change behavior. Results are delivered to the PCP at the point of care, paired with clinical decision support tailored to the patient's screening results. This information is delivered on the tablet computer, which is handed to the PCP by a Medical Assistant. CDS guides the PCP through a brief intervention specific to the DOMC, recommends clinical actions pertaining to the substance and risk level, and generates a printed summary for the patient. At each scheduled follow-up medical visit, the PCP receives a clinical reminder containing a summary of the patient's substance use and level of risk, paired with CDS that guides them through a follow-up brief intervention.
Study: NCT02990910

Intervention type: DRUG
Group type: OTHER
Intervention: Individualized opioid analgesia
Description: (a）positive result 10μg/kg morphine; negative result 50μg/kg morphine.

Intervention type: DEVICE
Group type: OTHER
Intervention: conventional opioid analgesia
Description: (b) all received 25μg/kg morphine
Study: NCT00695487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 9-d-tetra hydro cannabinol
Description: 0.125mg/kg iv one time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THC 9-d-tetra hydro cannabinol
Description: 0.125mg/kg iv one time
Study: NCT01991210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNIB0600A
Description: DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLD
Description: PLD will be administered at a dose of 40 mg/m\^2 IV every 4 weeks.
Study: NCT00657527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Cholesterol lowering diet
Study: NCT01563302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-STAT3Rx
Description: Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.
Study: NCT00635596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT110
Description: MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses
Study: NCT01397084

Intervention type: DRUG
Group type: OTHER
Intervention: esomeprazole 20 mg
Description: esomeprazole 20 mg once daily for 8 weeks
Study: NCT01993147

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dual task paradigm pilot
Study: NCT01654341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise, dietary and educational program
Study: NCT03410550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Training
Description: Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10).
Study: NCT04670848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleepiz One+ vs. polysomnography
Description: Simultaneous sleep recording with polysomnography and Sleepiz One+ device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleepiz One+ vs. polysomnography
Description: Simultaneous sleep recording with polysomnography and Sleepiz One+ device
Study: NCT01576263

Intervention type: DRUG
Intervention: Autologous blood transfusion with ropivacaine
Description: Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg
Study: NCT02345629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain/Symptom Questionnaire
Description: Pain and symptom questionnaire completed at baseline, by phone during first week of study, and once each month by phone during 6 month follow up.
Study: NCT01576263

Intervention type: DRUG
Intervention: Autologous blood transfusion with ropivacaine
Description: Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg.
Study: NCT04617509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A GS-248
Description: Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.

Intervention type: DRUG
Group type: OTHER
Intervention: Formulation A GS-248
Description: Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formulation B GS-248
Description: Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.

Intervention type: DRUG
Group type: OTHER
Intervention: Formulation B GS-248
Description: Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
Study: NCT00331682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study: NCT00232232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Study: NCT04531800

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrated growth factor
Description: In the concentrated growth factor (CGF) group, CGF was applied to the surgical area (n=14), and the area was primarily closed after additional releasing incisions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-concentrated growth factor
Description: In the non-CGF group, the surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy.
Study: NCT03176888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced-exertion, high-intensity interval training (REHIT)
Description: As in arm/group description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Up to six 30/40-minute sessions of face-to-face psychotherapy will be offered based on a cognitive model of adjustment to cancer utilizing cognitive and behavioral therapy techniques as described by Moorey \& Greer (2012)
Study: NCT05170620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser ablation
Description: Laser ablation will be done for the squamous intraepithelial lesions of the lower anogenital tracts.
Study: NCT00687219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Administered at 1.0 µg/kg/week SC for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening \>=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening \>=12g/dL and \<14g/dL; treatment duration is 48 weeks
Study: NCT01852006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Binder
Description: Abdominal Binding to increase end-expiratory gastric pressure by 5-8 centimetres of water at rest.